



(11) **EP 2 561 360 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**08.11.2017 Bulletin 2017/45**

(51) Int Cl.:  
**C12Q 1/68 (2006.01) G01N 33/53 (2006.01)**  
**G01N 33/553 (2006.01)**

(21) Application number: **11772606.7**

(86) International application number:  
**PCT/US2011/033184**

(22) Date of filing: **20.04.2011**

(87) International publication number:  
**WO 2011/133630 (27.10.2011 Gazette 2011/43)**

(54) **ISOLATING A TARGET ANALYTE FROM A BODY FLUID**

ISOLIERUNG EINES ZIELANALYTS AUS EINER KÖRPERFLÜSSIGKEIT

ISOLEMENT DE SUBSTANCE À ANALYSER CIBLE PROVENANT DE LIQUIDE BIOLOGIQUE

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(56) References cited:  
**WO-A1-95/31481 WO-A1-98/20148**  
**US-A- 5 466 574 US-A- 5 770 461**  
**US-A1- 2002 012 669 US-A1- 2007 183 935**  
**US-B1- 6 365 362**

(30) Priority: **21.04.2010 US 326588 P**  
**04.08.2010 US 850203**

(43) Date of publication of application:  
**27.02.2013 Bulletin 2013/09**

(73) Proprietor: **DNAE Group Holdings Limited**  
**London**  
**W12 7SB (GB)**

(72) Inventors:  
• **CLARIZIA, Lisa-Jo, Ann**  
**Albuquerque, NM 87106 (US)**  
• **ADAMS, Eddie, W.**  
**Albuquerque, NM 87108 (US)**  
• **DRYGA, Sergey, A.**  
**Rio Rancho, NM 87144 (US)**

(74) Representative: **Kirkham, Nicholas Andrew et al**  
**Graham Watt & Co. LLP**  
**St. Botolph's House**  
**7-9 St. Botolph's Road**  
**Sevenoaks, Kent TN13 3AJ (GB)**

- **MADONNA A J ET AL: "DETECTION OF BACTERIA FROM BIOLOGICAL MIXTURES USING IMMUNOMAGNETIC SEPARATION COMBINED WITH MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, JOHN WILEY & SONS, GB, vol. 15, no. 13, 1 January 2001 (2001-01-01), pages 1068-1074, XP001117759, ISSN: 0951-4198, DOI: 10.1002/RCM.344**
- **DRANCOURT ET AL.: 'Diagnosis of Mediterranean Spotted Fever by Indirect Immunofluorescence of Rickettsia conorii in Circulating Endothelial Cells Isolated with Monoclonal Antibody-Coated Immunomagnetic Beads.' THE JOURNAL OF INFECTIOUS DISEASES. vol. 166, no. 3, September 1992, pages 660 - 663, XP009173165**
- **FU ET AL.: 'Rapid detection of Escherichia coli 0157:H7 by Immunomagnetic Separation and Real-time PCR.' INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY. vol. 99, no. 1, 01 March 2005, pages 47 - 57, XP027663170**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 561 360 B1**

**Description**Filed of the Invention

5 **[0001]** The disclosure generally relates to using magnetic particles and magnets to isolate a target analyte from a body fluid sample.

Background

10 **[0002]** Blood-borne pathogens are a significant healthcare problem. A delayed or improper diagnosis of a bacterial infection can result in sepsis - a serious, and often deadly, inflammatory response to the infection. Sepsis is the 10<sup>th</sup> leading cause of death in the United States. Early detection of bacterial infections in blood is the key to preventing the onset of sepsis. Traditional methods of detection and identification of blood-borne infection include blood culture and antibiotic susceptibility assays. Those methods typically require culturing cells, which can be expensive and can take as long as 72 hours. Often, septic shock will occur before cell culture results can be obtained.

15 **[0003]** Alternative methods for detection of pathogens, particularly bacteria, have been described by others. Those methods include molecular detection methods, antigen detection methods, and metabolite detection methods. Molecular detection methods, whether involving hybrid capture or polymerase chain reaction (PCR), require high concentrations of purified DNA for detection. Both antigen detection and metabolite detection methods also require a relatively large amount of bacteria and have high limit of detection (usually > 10<sup>4</sup> CFU/mL), thus requiring an enrichment step prior to detection. This incubation/enrichment period is intended to allow for the growth of bacteria and an increase in bacterial cell numbers to more readily aid in identification. In many cases, a series of two or three separate incubations is needed to isolate the target bacteria. However, such enrichment steps require a significant amount of time (e.g., at least a few days to a week) and can potentially compromise test sensitivity by killing some of the cells sought to be measured.

20 **[0004]** There is a need for methods for isolating target analytes, such as bacteria, from a sample, such as a blood sample, without an additional enrichment step. There is also a need for methods of isolating target analytes that are fast and sensitive in order to provide data for patient treatment decisions in a clinically relevant time frame.

Summary

30 **[0005]** The present disclosure provides methods and devices for isolating pathogens in a biological sample. The invention allows the rapid detection of pathogen at very low levels in the sample; thus enabling early and accurate detection and identification of the pathogen. The invention is carried out with magnetic particles having a target-specific binding moiety. Methods of the invention involve introducing magnetic particles including a target-specific binding moiety to a body fluid sample in order to create a mixture, incubating the mixture to allow the particles to bind to a target, applying a magnetic field to capture target/magnetic particle complexes on a surface, and washing with a wash solution that reduces particle aggregation, thereby isolating target/magnetic particle complexes. A particular advantage of methods of the invention is for capture and isolation of bacteria and fungi directly from blood samples at low concentrations that are present in many clinical samples (as low as 1 CFU/ml of bacteria in a blood sample).

35 **[0006]** The target-specific binding moiety will depend on the target to be captured. The moiety may be any capture moiety known in the art, such as an antibody, an aptamer, a nucleic acid, a protein, a receptor, a phage or a ligand. In particular embodiments, the target-specific binding moiety is an antibody. In certain embodiments, the antibody is specific for bacteria. In other embodiments, the antibody is specific for fungi.

40 **[0007]** The target analyte refers to the target that will be captured and isolated by methods of the invention. The target may be bacteria, fungi, protein, a cell, a virus, a nucleic acid, a receptor, a ligand, or any molecule known in the art. In certain embodiments, the target is a pathogenic bacteria. In other embodiments, the target is a gram positive or gram negative bacteria. Exemplary bacterial species that may be captured and isolated by methods of the invention include E. coli, Listeria, Clostridium, Mycobacterium, Shigella, Borrelia, Campylobacter, Bacillus, Salmonella, Staphylococcus, Enterococcus, Pneumococcus, Streptococcus, and a combination thereof.

45 **[0008]** Methods of the invention may be performed with any type of magnetic particle. Magnetic particles generally fall into two broad categories. The first category includes particles that are permanently magnetizable, or ferromagnetic; and the second category includes particles that demonstrate bulk magnetic behavior only when subjected to a magnetic field. The latter are referred to as magnetically responsive particles. Materials displaying magnetically responsive behavior are sometimes described as superparamagnetic. However, materials exhibiting bulk ferromagnetic properties, e.g., magnetic iron oxide, may be characterized as superparamagnetic when provided in crystals of about 30 nm or less in diameter. Larger crystals of ferromagnetic materials, by contrast, retain permanent magnet characteristics after exposure to a magnetic field and tend to aggregate thereafter due to strong particle-particle interaction. In certain embodiments, the particles are superparamagnetic beads. In other embodiments, the magnetic particles include at least 70% super-

paramagnetic beads by weight. In certain embodiments, the superparamagnetic beads are from about 100 nm to about 250 nm in diameter. In certain embodiments, the magnetic particle is an iron-containing magnetic particle. In other embodiments, the magnetic particle includes iron oxide or iron platinum.

**[0009]** In certain embodiments, the incubating step includes incubating the mixture in a buffer that inhibits cell lysis. In certain embodiments, the buffer includes Tris(hydroxymethyl)-aminomethane hydrochloride at a concentration of between about 50mM and about 100mM, preferably about 75 mM. In other embodiments, methods of the disclosure further include retaining the magnetic particles in a magnetic field during the washing step. Methods of the invention may be used with any body fluid. Exemplary body fluids include blood, sputum, serum, plasma, urine, saliva, sweat, and cerebral spinal fluid.

**[0010]** Another aspect provides methods for isolating a target microorganism from a body fluid sample including introducing magnetic particles having a target-specific binding moiety to a body fluid sample in order to create a mixture, incubating the mixture to allow the particles to bind to the target, applying a magnetic field to isolate on a surface magnetic particles to which target is bound, washing the mixture in a wash solution that reduces particle aggregation, and lysing the captured bacteria and extracting DNA for further analysis by PCR, microarray hybridization or sequencing.

**[0011]** Another aspect provides methods for isolating as low as 1 CFU/ml of bacteria in a blood sample including introducing superparamagnetic particles having a diameter from about 100 nm to about 250 nm and having a bacteria-specific binding moiety to a body fluid sample in order to create a mixture, incubating said mixture to allow said particles to bind to a bacteria, applying a magnetic field to isolate on a surface bacteria/magnetic particle complexes, and washing the mixture in a wash solution that reduces particle aggregation, thereby isolating as low as 1 viable CFU/ml of bacteria in the blood sample.

#### Detailed Description

**[0012]** The disclosure generally relates to using magnetic particles that capture target pathogens in a body fluid sample and magnets to isolate the target. Methods of the disclosure involve introducing magnetic particles including a target-specific binding moiety to a body fluid sample in order to create a mixture, incubating the mixture to allow the particles to bind to a target, applying a magnetic field to capture target/magnetic particle complexes on a surface, and washing the mixture in a wash solution that reduces particle aggregation, thereby isolating target/magnetic particle complexes. Certain fundamental technologies and principles are associated with binding magnetic materials to target entities and subsequently separating by use of magnet fields and gradients. Such fundamental technologies and principles are known in the art and have been previously described, such as those described in Janeway (Immunobiology, 6th edition, Garland Science Publishing). Methods of the disclosure involve collecting a body fluid having a target analyte in a container, such as a blood collection tube (e.g., VACUTAINER, test tube specifically designed for venipuncture, commercially available from Becton, Dickinson and company). In certain embodiments, a solution is added that prevents or reduces aggregation of endogenous aggregating factors, such as heparin in the case of blood.

**[0013]** A body fluid refers to a liquid material derived from, for example, a human or other mammal. Such body fluids include, but are not limited to, mucus, blood, plasma, serum, serum derivatives, bile, phlegm, saliva, sweat, amniotic fluid, mammary fluid, urine, sputum, and cerebrospinal fluid (CSF), such as lumbar or ventricular CSF. A body fluid may also be a fine needle aspirate. A body fluid also may be media containing cells or biological material. In particular embodiments, the fluid is blood.

**[0014]** Methods of the invention may be used to detect any target analyte. The target analyte refers to the substance in the sample that will be captured and isolated by methods of the invention. The target may be bacteria, fungi, a protein, a cell (such as a cancer cell, a white blood cell a virally infected cell, or a fetal cell circulating in maternal circulation), a virus, a nucleic acid (e.g., DNA or RNA), a receptor, a ligand, a hormone, a drug, a chemical substance, or any molecule known in the art. In certain embodiments, the target is a pathogenic bacteria. In other embodiments, the target is a gram positive or gram negative bacteria. Exemplary bacterial species that may be captured and isolated by methods of the invention include E. coli, Listeria, Clostridium, Mycobacterium, Shigella, Borrelia, Campylobacter, Bacillus, Salmonella, Staphylococcus, Enterococcus, Pneumococcus, Streptococcus, and a combination thereof.

**[0015]** The sample is then mixed with magnetic particles including a target-specific binding moiety to generate a mixture that is allowed to incubate such that the particles bind to a target in the sample, such as a bacterium in a blood sample. The mixture is allowed to incubate for a sufficient time to allow for the particles to bind to the target analyte. The process of binding the magnetic particles to the target analytes associates a magnetic moment with the target analytes, and thus allows the target analytes to be manipulated through forces generated by magnetic fields upon the attached magnetic moment.

**[0016]** In general, incubation time will depend on the desired degree of binding between the target analyte and the magnetic beads (e.g., the amount of moment that would be desirably attached to the target), the amount of moment per target, the amount of time of mixing, the type of mixing, the reagents present to promote the binding and the binding chemistry system that is being employed. Incubation time can be anywhere from about 5 seconds to a few days.

Exemplary incubation times range from about 10 seconds to about 2 hours. Binding occurs over a wide range of temperatures, generally between 15 °C and 40 °C.

**[0017]** Methods of the invention may be performed with any type of magnetic particle. Production of magnetic particles and particles for use with the invention are known in the art. See for example Giaever (U.S. 3,970,518), Senyi et al. (U.S. 4,230,685), Dodin et al. (U.S. 4,677,055), Whitehead et al. (U.S. 4,695,393), Benjamin et al. (U.S. 5,695,946), Giaever (U.S. 4,018,886), Rembaum (U.S. 4,267,234), Molday (U.S. 4,452,773), Whitehead et al. (U.S. 4,554,088), Forrest (U.S. 4,659,678), Liberti et al. (U.S. 5,186,827), Own et al. (U.S. 4,795,698), and Liberti et al. (WO 91/02811). Magnetic particles generally fall into two broad categories. The first category includes particles that are permanently magnetizable, or ferromagnetic; and the second category includes particles that demonstrate bulk magnetic behavior only when subjected to a magnetic field. The latter are referred to as magnetically responsive particles. Materials displaying magnetically responsive behavior are sometimes described as superparamagnetic. However, materials exhibiting bulk ferromagnetic properties, e.g., magnetic iron oxide, may be characterized as superparamagnetic when provided in crystals of about 30 nm or less in diameter. Larger crystals of ferromagnetic materials, by contrast, retain permanent magnet characteristics after exposure to a magnetic field and tend to aggregate thereafter due to strong particle-particle interaction. In certain embodiments, the particles are superparamagnetic beads. In certain embodiments, the magnetic particle is an iron containing magnetic particle. In other embodiments, the magnetic particle includes iron oxide or iron platinum.

**[0018]** In certain embodiments, the magnetic particles include at least about 10% superparamagnetic beads by weight, at least about 20% superparamagnetic beads by weight, at least about 30% superparamagnetic beads by weight, at least about 40% superparamagnetic beads by weight, at least about 50% superparamagnetic beads by weight, at least about 60% superparamagnetic beads by weight, at least about 70% superparamagnetic beads by weight, at least about 80% superparamagnetic beads by weight, at least about 90% superparamagnetic beads by weight, at least about 95% superparamagnetic beads by weight, or at least about 99% superparamagnetic beads by weight. In a particular embodiment, the magnetic particles include at least about 70% superparamagnetic beads by weight.

**[0019]** In certain embodiments, the superparamagnetic beads are less than 100 nm in diameter. In other embodiments, the superparamagnetic beads are about 150 nm in diameter, are about 200 nm in diameter, are about 250 nm in diameter, are about 300 nm in diameter, are about 350 nm in diameter, are about 400 nm in diameter, are about 500 nm in diameter, or are about 1000 nm in diameter. In a particular embodiment, the superparamagnetic beads are from about 100 nm to about 250 nm in diameter.

**[0020]** In certain embodiments, the particles are beads (e.g., nanoparticles) that incorporate magnetic materials, or magnetic materials that have been functionalized, or other configurations as are known in the art. In certain embodiments, nanoparticles may be used that include a polymer material that incorporates magnetic material(s), such as nanometal material(s). When those nanometal material(s) or crystal(s), such as Fe<sub>3</sub>O<sub>4</sub>, are superparamagnetic, they may provide advantageous properties, such as being capable of being magnetized by an external magnetic field, and demagnetized when the external magnetic field has been removed. This may be advantageous for facilitating sample transport into and away from an area where the sample is being processed without undue bead aggregation.

**[0021]** One or more or many different nanometal(s) may be employed, such as Fe<sub>3</sub>O<sub>4</sub>, FePt, or Fe, in a core-shell configuration to provide stability, and/or various others as may be known in the art. In many applications, it may be advantageous to have a nanometal having as high a saturated moment per volume as possible, as this may maximize gradient related forces, and/or may enhance a signal associated with the presence of the beads. It may also be advantageous to have the volumetric loading in a bead be as high as possible, for the same or similar reason(s). In order to maximize the moment provided by a magnetizable nanometal, a certain saturation field may be provided. For example, for Fe<sub>3</sub>O<sub>4</sub> superparamagnetic particles, this field may be on the order of about 0.3T.

**[0022]** The size of the nanometal containing bead may be optimized for a particular application, for example, maximizing moment loaded upon a target, maximizing the number of beads on a target with an acceptable detectability, maximizing desired force-induced motion, and/or maximizing the difference in attached moment between the labeled target and non-specifically bound targets or bead aggregates or individual beads. While maximizing is referenced by example above, other optimizations or alterations are contemplated, such as minimizing or otherwise desirably affecting conditions.

**[0023]** In an exemplary embodiment, a polymer bead containing 80 wt% Fe<sub>3</sub>O<sub>4</sub> superparamagnetic particles, or for example, 90 wt% or higher superparamagnetic particles, is produced by encapsulating superparamagnetic particles with a polymer coating to produce a bead having a diameter of about 250 nm.

**[0024]** Magnetic particles for use with methods of the invention have a target-specific binding moiety that allows for the particles to specifically bind the target of interest in the sample. The target-specific moiety may be any molecule known in the art and will depend on the target to be captured and isolated. Exemplary target-specific binding moieties include nucleic acids, proteins, ligands, antibodies, aptamers, and receptors.

**[0025]** In particular embodiments, the target-specific binding moiety is an antibody, such as an antibody that binds a particular bacterium. General methodologies for antibody production, including criteria to be considered when choosing an animal for the production of antisera, are described in Harlow et al. (Antibodies, Cold Spring Harbor Laboratory, pp.

93-117, 1988). For example, an animal of suitable size such as goats, dogs, sheep, mice, or camels are immunized by administration of an amount of immunogen, such the target bacteria, effective to produce an immune response. An exemplary protocol is as follows. The animal is injected with 100 milligrams of antigen resuspended in adjuvant, for example Freund's complete adjuvant, dependent on the size of the animal, followed three weeks later with a subcutaneous injection of 100 micrograms to 100 milligrams of immunogen with adjuvant dependent on the size of the animal, for example Freund's incomplete adjuvant. Additional subcutaneous or intraperitoneal injections every two weeks with adjuvant, for example Freund's incomplete adjuvant, are administered until a suitable titer of antibody in the animal's blood is achieved. Exemplary titers include a titer of at least about 1:5000 or a titer of 1:100,000 or more, i.e., the dilution having a detectable activity. The antibodies are purified, for example, by affinity purification on columns containing protein G resin or target-specific affinity resin.

**[0026]** The technique of *in vitro* immunization of human lymphocytes is used to generate monoclonal antibodies. Techniques for *in vitro* immunization of human lymphocytes are well known to those skilled in the art. See, e.g., Inai, et al., *Histochemistry*, 99(5):335 362, May 1993; Mulder, et al., *Hum. Immunol.*, 36(3):186 192, 1993; Harada, et al., *J. Oral Pathol. Med.*, 22(4):145 152, 1993; Stauber, et al., *J. Immunol. Methods*, 161(2):157 168, 1993; and Venkateswaran, et al., *Hybridoma*, 11(6) 729 739, 1992. These techniques can be used to produce antigen-reactive monoclonal antibodies, including antigen-specific IgG, and IgM monoclonal antibodies.

**[0027]** Any antibody or fragment thereof having affinity and specific for the bacteria of interest is within the scope of the invention provided herein. Immunomagnetic beads against *Salmonella* are provided in Vermunt et al. (*J. Appl. Bact.* 72:112, 1992). Immunomagnetic beads against *Staphylococcus aureus* are provided in John et al. (*J. Clin. Microbiol.* 27:1631, 1989). Immunomagnetic beads against *Listeria* are provided in Skjerve et al. (*Appl. Env. Microbiol.* 56:3478, 1990). Immunomagnetic beads against *Escherichia coli* are provided in Lund et al. (*J. Clin. Microbiol.* 29:2259, 1991).

**[0028]** Methods for attaching the target-specific binding moiety to the magnetic particle are known in the art. Coating magnetic particles with antibodies is well known in the art, see for example Harlow et al. (*Antibodies*, Cold Spring Harbor Laboratory, 1988), Hunter et al. (*Immunoassays for Clinical Chemistry*, pp. 147-162, eds., Churchill Livingstone, Edinburgh, 1983), and Stanley (*Essentials in Immunology and Serology*, Delmar, pp. 152-153, 2002). Such methodology can easily be modified by one of skill in the art to bind other types of target-specific binding moieties to the magnetic particles. Certain types of magnetic particles coated with a functional moiety are commercially available from Sigma-Aldrich (St. Louis, MO).

**[0029]** In certain embodiments, a buffer solution is added to the sample along with the magnetic beads. An exemplary buffer includes Tris(hydroxymethyl)-aminomethane hydrochloride at a concentration of about 75mM. It has been found that the buffer composition, mixing parameters (speed, type of mixing, such as rotation, shaking etc., and temperature) influence binding. It is important to maintain osmolality of the final solution (e.g., blood + buffer) to maintain high label efficiency. In certain embodiments, buffers used in methods of the invention are designed to prevent lysis of blood cells, facilitate efficient binding of targets with magnetic beads and to reduce formation of bead aggregates. It has been found that the buffer solution containing 300 mM NaCl, 75 mM Tris-HCl pH 8.0 and 0.1% Tween 20 meets these design goals.

**[0030]** Without being limited by any particular theory or mechanism of action, it is believed that sodium chloride is mainly responsible for maintaining osmolality of the solution and for the reduction of non-specific binding of magnetic bead through ionic interaction. Tris(hydroxymethyl)-aminomethane hydrochloride is a well established buffer compound frequently used in biology to maintain pH of a solution. It has been found that 75 mM concentration is beneficial and sufficient for high binding efficiency. Likewise, Tween 20 is widely used as a mild detergent to decrease nonspecific attachment due to hydrophobic interactions. Various assays use Tween 20 at concentrations ranging from 0.01% to 1%. The 0.1% concentration appears to be optimal for the efficient labeling of bacteria, while maintaining blood cells intact.

**[0031]** An alternative approach to achieve high binding efficiency while reducing time required for the binding step is to use static mixer, or other mixing devices that provide efficient mixing of viscous samples at high flow rates, such as at or around 5 mL/min. In one embodiment, the sample is mixed with binding buffer in ratio of, or about, 1:1, using a mixing interface connector. The diluted sample then flows through a mixing interface connector where it is mixed with target-specific nanoparticles. Additional mixing interface connectors providing mixing of sample and antigen-specific nanoparticles can be attached downstream to improve binding efficiency. The combined flow rate of the labeled sample is selected such that it is compatible with downstream processing.

**[0032]** After binding of the magnetic particles to the target analyte in the mixture to form target/magnetic particle complexes, a magnetic field is applied to the mixture to capture the complexes on a surface. Components of the mixture that are not bound to magnetic particles will not be affected by the magnetic field and will remain free in the mixture. Methods and apparatuses for separating target/magnetic particle complexes from other components of a mixture are known in the art. For example, a steel mesh may be coupled to a magnet, a linear channel or channels may be configured with adjacent magnets, or quadrupole magnets with annular flow may be used. Other methods and apparatuses for separating target/magnetic particle complexes from other components of a mixture are shown in Rao et al. (U.S. 6,551,843), Liberti et al. (U.S. 5,622,831), Hatch et al. (U.S. 6,514,415), Benjamin et al. (U.S. 5,695,946), Liberti et al. (U.S. 5,186,827), Wang et al. (U.S. 5,541,072), Liberti et al. (U.S. 5,466,574), and Terstappen et al. (U.S. 6,623,983).

In certain embodiments, the magnetic capture is achieved at high efficiency by utilizing a flow-through capture cell with a number of strong rare earth bar magnets placed perpendicular to the flow of the sample. When using a flow chamber with flow path cross-section 0.5 mm x 20 mm (h x w) and 7 bar NdFeB magnets, the flow rate could be as high as 5 mL/min or more, while achieving capture efficiency close to 100%.

**[0033]** The above described type of magnetic separation produces efficient capture of a target analyte and the removal of a majority of the remaining components of a sample mixture. However, such a process produces a sample that contains a very high percent of magnetic particles that are not bound to target analytes because the magnetic particles are typically added in excess, as well as non-specific target entities. Non-specific target entities may for example be bound at a much lower efficiency, for example 1% of the surface area, while a target of interest might be loaded at 50% or nearly 100% of the available surface area or available antigenic sites. However, even 1 % loading may be sufficient to impart force necessary for trapping in a magnetic gradient flow cell or sample chamber.

**[0034]** For example, in the case of immunomagnetic binding of bacteria or fungi in a blood sample, the sample may include: bound targets at a concentration of about 1/mL or a concentration less than about 10<sup>6</sup>/mL; background particles at a concentration of about 10<sup>7</sup>/ml to about 10<sup>10</sup>/ml; and non-specific targets at a concentration of about 10/ml to about 10<sup>5</sup>/ml.

**[0035]** The presence of magnetic particles that are not bound to target analytes and non-specific target entities on the surface that includes the target/magnetic particle complexes interferes with the ability to successfully detect the target of interest. The magnetic capture of the resulting mix, and close contact of magnetic particles with each other and bound targets, result in the formation of aggregate that is hard to dispense and which might be resistant or inadequate for subsequent processing or analysis steps. In order to remove magnetic particles that are not bound to target analytes and non-specific target entities, methods of the invention involve washing the surface with a wash solution that reduces particle aggregation, thereby isolating target/magnetic particle complexes from the magnetic particles that are not bound to target analytes and non-specific target entities. The wash solution minimizes the formation of the aggregates.

**[0036]** Methods of the invention may use any wash solution that imparts a net negative charge to the magnetic particle that is not sufficient to disrupt interaction between the target-specific moiety of the magnetic particle and the target analyte. Without being limited by any particular theory or mechanism of action, it is believed that attachment of the negatively charged molecules in the wash solution to magnetic particles provides net negative charge to the particles and facilitates dispersal of non-specifically aggregated particles. At the same time, the net negative charge is not sufficient to disrupt strong interaction between the target-specific moiety of the magnetic particle and the target analyte (e.g., an antibody-antigen interaction). Exemplary solutions include heparin, Tris-HCl, Tris-borate-EDTA (TBE), Tris-acetate-EDTA (TAE), Tris-cacodylate, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid), PBS (phosphate buffered saline), PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid), MES (2-N-morpholino)ethanesulfonic acid), Tricine (N-(Tri(hydroxymethyl)methyl)glycine), and similar buffering agents. In certain embodiments, only a single wash cycle is performed. In other embodiments, more than one wash cycle is performed.

**[0037]** In particular embodiments, the wash solution includes heparin. For embodiments in which the body fluid sample is blood, the heparin also reduces probability of clotting of blood components after magnetic capture. The bound targets are washed with heparin-containing buffer 1-3 times to remove blood components and to reduce formation of aggregates.

**[0038]** Once the target/magnetic particle complexes are isolated, the target may be analyzed by a multitude of existing technologies, such as miniature NMR, Polymerase Chain Reaction (PCR), mass spectrometry, fluorescent labeling and visualization using microscopic observation, fluorescent *in situ* hybridization (FISH), growth-based antibiotic sensitivity tests, and variety of other methods that may be conducted with purified target without significant contamination from other sample components. In one embodiment, isolated bacteria are lysed with a chaotropic solution, and DNA is bound to DNA extraction resin. After washing of the resin, the bacterial DNA is eluted and used in quantitative RT-PCR to detect the presence of a specific species, and/or, subclasses of bacteria.

**[0039]** In another embodiment, captured bacteria is removed from the magnetic particles to which they are bound and the processed sample is mixed with fluorescent labeled antibodies specific to the bacteria or fluorescent Gram stain. After incubation, the reaction mixture is filtered through 0.2 μm to 1.0 μm filter to capture labeled bacteria while allowing majority of free beads and fluorescent labels to pass through the filter. Bacteria is visualized on the filter using microscopic techniques, e.g. direct microscopic observation, laser scanning or other automated methods of image capture. The presence of bacteria is detected through image analysis. After the positive detection by visual techniques, the bacteria can be further characterized using PCR or genomic methods.

**[0040]** Detection of bacteria of interest can be performed by use of nucleic acid probes following procedures which are known in the art. Suitable procedures for detection of bacteria using nucleic acid probes are described, for example, in Stackebrandt et al. (U.S. 5,089,386), King et al. (WO 90/08841), Foster et al. (WO 92/15883), and Cossart et al. (WO 89/06699).

**[0041]** A suitable nucleic acid probe assay generally includes sample treatment and lysis, hybridization with selected probe(s), hybrid capture, and detection. Lysis of the bacteria is necessary to release the nucleic acid for the probes. The nucleic acid target molecules are released by treatment with any of a number of lysis agents, including alkali (such as

NaOH), guanidine salts (such as guanidine thiocyanate), enzymes (such as lysozyme, mutanolysin and proteinase K), and detergents. Lysis of the bacteria, therefore, releases both DNA and RNA, particularly ribosomal RNA and chromosomal DNA both of which can be utilized as the target molecules with appropriate selection of a suitable probe. Use of rRNA as the target molecule(s), may be advantageous because rRNAs constitute a significant component of cellular mass, thereby providing an abundance of target molecules. The use of rRNA probes also enhances specificity for the bacteria of interest, that is, positive detection without undesirable cross-reactivity which can lead to false positives or false detection.

**[0042]** Hybridization includes addition of the specific nucleic acid probes. In general, hybridization is the procedure by which two partially or completely complementary nucleic acids are combined, under defined reaction conditions, in an anti-parallel fashion to form specific and stable hydrogen bonds. The selection or stringency of the hybridization/reaction conditions is defined by the length and base composition of the probe/target duplex, as well as by the level and geometry of mis-pairing between the two nucleic acid strands. Stringency is also governed by such reaction parameters as temperature, types and concentrations of denaturing agents present and the type and concentration of ionic species present in the hybridization solution.

**[0043]** The hybridization phase of the nucleic acid probe assay is performed with a single selected probe or with a combination of two, three or more probes. Probes are selected having sequences which are homologous to unique nucleic acid sequences of the target organism. In general, a first capture probe is utilized to capture formed hybrid molecules. The hybrid molecule is then detected by use of antibody reaction or by use of a second detector probe which may be labelled with a radioisotope (such as phosphorus-32) or a fluorescent label (such as fluorescein) or chemiluminescent label.

**[0044]** Detection of bacteria of interest can also be performed by use of PCR techniques. A suitable PCR technique is described, for example, in Verhoef et al. (WO 92/08805). Such protocols may be applied directly to the bacteria captured on the magnetic beads. The bacteria is combined with a lysis buffer and collected nucleic acid target molecules are then utilized as the template for the PCR reaction.

**[0045]** For detection of the selected bacteria by use of antibodies, isolated bacteria are contacted with antibodies specific to the bacteria of interest. As noted above, either polyclonal or monoclonal antibodies can be utilized, but in either case have affinity for the particular bacteria to be detected. These antibodies, will adhere/bind to material from the specific target bacteria. With respect to labeling of the antibodies, these are labeled either directly or indirectly with labels used in other known immunoassays. Direct labels may include fluorescent, chemiluminescent, bioluminescent, radioactive, metallic, biotin or enzymatic molecules. Methods of combining these labels to antibodies or other macromolecules are well known to those in the art. Examples include the methods of Hijmans, W. et al. (1969), Clin. Exp. Immunol. 4, 457-, for fluorescein isothiocyanate, the method of Goding, J. W. (1976), J. Immunol. Meth. 13,215-, for tetramethylrhodamine isothiocyanate, and the method of Ingrassia, E. (1980), Meth. in Enzymol. 70, 419-439 for enzymes.

**[0046]** These detector antibodies may also be labeled indirectly. In this case the actual detection molecule is attached to a secondary antibody or other molecule with binding affinity for the anti-bacteria cell surface antibody. If a secondary antibody is used it is preferably a general antibody to a class of antibody (IgG and IgM) from the animal species used to raise the anti-bacteria cell surface antibodies. For example, the second antibody may be conjugated to an enzyme, either alkaline phosphatase or to peroxidase. To detect the label, after the bacteria of interest is contacted with the second antibody and washed, the isolated component of the sample is immersed in a solution containing a chromogenic substrate for either alkaline phosphatase or peroxidase. A chromogenic substrate is a compound that can be cleaved by an enzyme to result in the production of some type of detectable signal which only appears when the substrate is cleaved from the base molecule. The chromogenic substrate is colorless, until it reacts with the enzyme, at which time an intensely colored product is made. Thus, material from the bacteria colonies adhered to the membrane sheet will become an intense blue/purple/black color, or brown/red while material from other colonies will remain colorless. Examples of detection molecules include fluorescent substances, such as 4-methylumbelliferyl phosphate, and chromogenic substances, such as 4-nitrophenylphosphate, 3,3',5,5'-tetramethylbenzidine and 2,2'-azino-di-[3-ethylbenz-thiazoliane sulfonate (6)]. In addition to alkaline phosphatase and peroxidase, other useful enzymes include  $\beta$ -galactosidase,  $\beta$ -glucuronidase,  $\alpha$ -glucosidase,  $\beta$ -glucosidase,  $\alpha$ -mannosidase, galactose oxidase, glucose oxidase and hexokinase.

**[0047]** Detection of bacteria of interest using NMR may be accomplished as follows. In the use of NMR as a detection methodology, in which a sample is delivered to a detector coil centered in a magnet, the target of interest, such as a magnetically labeled bacterium, may be delivered by a fluid medium, such as a fluid substantially composed of water. In such a case, the magnetically labeled target may go from a region of very low magnetic field to a region of high magnetic field, for example, a field produced by an about 1 to about 2 Tesla magnet. In this manner, the sample may traverse a magnetic gradient, on the way into the magnet and on the way out of the magnet. As may be seen via equations 1 and 2 below, the target may experience a force pulling into the magnet in the direction of sample flow on the way into the magnet, and a force into the magnet in the opposite direction of flow on the way out of the magnet. The target may experience a retaining force trapping the target in the magnet if flow is not sufficient to overcome the gradient force.

$$m \cdot (\nabla B) = F$$

Equation 1

$$v_t = -F / (6 \cdot \eta \cdot r)$$

Equation 2

where  $\eta$  is the viscosity,  $r$  is the bead diameter,  $F$  is the vector force,  $B$  is the vector field, and  $m$  is the vector moment of the bead

**[0048]** Magnetic fields on a path into a magnet may be non-uniform in the transverse direction with respect to the flow into the magnet. As such, there may be a transverse force that pulls targets to the side of a container or a conduit that provides the sample flow into the magnet. Generally, the time it takes a target to reach the wall of a conduit is associated with the terminal velocity and is lower with increasing viscosity. The terminal velocity is associated with the drag force, which may be indicative of creep flow in certain cases. In general, it may be advantageous to have a high viscosity to provide a higher drag force such that a target will tend to be carried with the fluid flow through the magnet without being trapped in the magnet or against the conduit walls.

**[0049]** Newtonian fluids have a flow characteristic in a conduit, such as a round pipe, for example, that is parabolic, such that the flow velocity is zero at the wall, and maximal at the center, and having a parabolic characteristic with radius. The velocity decreases in a direction toward the walls, and it is easier to magnetically trap targets near the walls, either with transverse gradients force on the target toward the conduit wall, or in longitudinal gradients sufficient to prevent target flow in the pipe at any position. In order to provide favorable fluid drag force to keep the samples from being trapped in the conduit, it may be advantageous to have a plug flow condition, wherein the fluid velocity is substantially uniform as a function of radial position in the conduit.

**[0050]** When NMR detection is employed in connection with a flowing sample, the detection may be based on a perturbation of the NMR water signal caused by a magnetically labeled target (Sillerud et al., JMR (Journal of Magnetic Resonance), vol. 181, 2006). In such a case, the sample may be excited at time 0, and after some delay, such as about 50ms or about 100ms, an acceptable measurement (based on a detected NMR signal) may be produced. Alternatively, such a measurement may be produced immediately after excitation, with the detection continuing for some duration, such as about 50ms or about 100ms. It may be advantageous to detect the NMR signal for substantially longer time durations after the excitation.

**[0051]** By way of example, the detection of the NMR signal may continue for a period of about 2 seconds in order to record spectral information at high-resolution. In the case of parabolic or Newtonian flow, the perturbation excited at time 0 is typically smeared because the water around the perturbation source travels at different velocity, depending on radial position in the conduit. In addition, spectral information may be lost due to the smearing or mixing effects of the differential motion of the sample fluid during signal detection. When carrying out an NMR detection application involving a flowing fluid sample, it may be advantageous to provide plug-like sample flow to facilitate desirable NMR contrast and/or desirable NMR signal detection.

**[0052]** Differential motion within a flowing Newtonian fluid may have deleterious effects in certain situations, such as a situation in which spatially localized NMR detection is desired, as in magnetic resonance imaging. In one example, a magnetic object, such as a magnetically labeled bacterium, is flowed through the NMR detector and its presence and location are detected using MRI techniques. The detection may be possible due to the magnetic field of the magnetic object, since this field perturbs the magnetic field of the fluid in the vicinity of the magnetic object. The detection of the magnetic object is improved if the fluid near the object remains near the object. Under these conditions, the magnetic perturbation may be allowed to act longer on any given volume element of the fluid, and the volume elements of the fluid so affected will remain in close spatial proximity. Such a stronger, more localized magnetic perturbation will be more readily detected using NMR or MRI techniques.

**[0053]** If a Newtonian fluid is used to carry the magnetic objects through the detector, the velocity of the fluid volume elements will depend on radial position in the fluid conduit. In such a case, the fluid near a magnetic object will not remain near the magnetic object as the object flows through the detector. The effect of the magnetic perturbation of the object on the surrounding fluid may be smeared out in space, and the strength of the perturbation on any one fluid volume element may be reduced because that element does not stay within range of the perturbation. The weaker, less-well-localized perturbation in the sample fluid may be undetectable using NMR or MRI techniques.

**[0054]** Certain liquids, or mixtures of liquids, exhibit non-parabolic flow profiles in circular conduits. Such fluids may exhibit non-Newtonian flow profiles in other conduit shapes. The use of such a fluid may prove advantageous as the detection fluid in an application employing an NMR-based detection device. Any such advantageous effect may be attributable to high viscosity of the fluid, a plug-like flow profile associated with the fluid, and/or other characteristic(s) attributed to the fluid that facilitate detection. As an example, a shear-thinning fluid of high viscosity may exhibit a flow velocity profile that is substantially uniform across the central regions of the conduit cross-section. The velocity profile

of such a fluid may transition to a zero or very low value near or at the walls of the conduit, and this transition region may be confined to a very thin layer near the wall.

5 [0055] Not all fluids, or all fluid mixtures, are compatible with the NMR detection methodology. In one example, a mixture of glycerol and water can provide high viscosity, but the NMR measurement is degraded because separate NMR signals are detected from the water and glycerol molecules making up the mixture. This can undermine the sensitivity of the NMR detector. In another example, the non-water component of the fluid mixture can be chosen to have no NMR signal, which may be achieved by using a perdeuterated fluid component, for example, or using a perfluorinated fluid component. This approach may suffer from the loss of signal intensity since a portion of the fluid in the detection coil does not produce a signal.

10 [0056] Another approach may be to use a secondary fluid component that constitutes only a small fraction of the total fluid mixture. Such a low-concentration secondary fluid component can produce an NMR signal that is of negligible intensity when compared to the signal from the main component of the fluid, which may be water. It may be advantageous to use a low-concentration secondary fluid component that does not produce an NMR signal in the detector. For example, a perfluorinated or perdeuterated secondary fluid component may be used.

15 The fluid mixture used in the NMR detector may include one, two, or more than two secondary components in addition to the main fluid component. The fluid components employed may act in concert to produce the desired fluid flow characteristics, such as high-viscosity and/or plug flow. The fluid components may be useful for providing fluid characteristics that are advantageous for the performance of the NMR detector, for example by providing NMR relaxation times that allow faster operation or higher signal intensities.

20 [0057] A non-Newtonian fluid may provide additional advantages for the detection of objects by NMR or MRI techniques. As one example, the objects being detected may all have substantially the same velocity as they go through the detection coil. This characteristic velocity may allow simpler or more robust algorithms for the analysis of the detection data. As another example, the objects being detected may have fixed, known, and uniform velocity. This may prove advantageous in devices where the position of the detected object at later times is needed, such as in a device that has a sequestration chamber or secondary detection chamber down-stream from the NMR or MRI detection coil, for example.

25 [0058] In an exemplary embodiment, sample delivery into and out of a 1.7T cylindrical magnet using a fluid delivery medium containing 0.1% to 0.5 % Xanthan gum in water was successfully achieved. Such delivery is suitable to provide substantially plug-like flow, high viscosity, such as from about 10cP to about 3000cP, and good NMR contrast in relation to water. Xanthan gum acts as a non-Newtonian fluid, having characteristics of a non-Newtonian fluid that are well known in the art, and does not compromise NMR signal characteristics desirable for good detection in a desirable mode of operation.

30 [0059] In certain embodiments, methods of the invention are useful for direct detection of bacteria from blood. Such a process is described here. Sample is collected in sodium heparin tube by venipuncture, acceptable sample volume is about 1 mL to 10 mL. Sample is diluted with binding buffer and superparamagnetic particles having target-specific binding moieties are added to the sample, followed by incubation on a shaking incubator at 37 °C for about 30 min to 120 min. Alternative mixing methods can also be used. In a particular embodiment, sample is pumped through a static mixer, such that reaction buffer and magnetic beads are added to the sample as the sample is pumped through the mixer. This process allows for efficient integration of all components into a single fluidic part, avoids moving parts and separate incubation vessels and reduces incubation time.

35 [0060] Capture of the labeled targets allows for the removal of blood components and reduction of sample volume from 30 mL to 5 mL. The capture is performed in a variety of magnet/flow configurations. In certain embodiments, methods include capture in a sample tube on a shaking platform or capture in a flow-through device at flow rate of 5 mL/min, resulting in total capture time of 6 min.

40 [0061] After capture, the sample is washed with wash buffer including heparin to remove blood components and free beads. The composition of the wash buffer is optimized to reduce aggregation of free beads, while maintaining the integrity of the bead/target complexes.

45 [0062] The detection method is based on a miniature NMR detector tuned to the magnetic resonance of water. When the sample is magnetically homogenous (no bound targets), the NMR signal from water is clearly detectable and strong. The presence of magnetic material in the detector coil disturbs the magnetic field, resulting in reduction in water signal. One of the primary benefits of this detection method is that there is no magnetic background in biological samples which significantly reduces the requirements for stringency of sample processing. In addition, since the detected signal is generated by water, there is a built-in signal amplification which allows for the detection of a single labeled bacterium.

50 [0063] This method provides for isolation and detection of as low as or even lower than 1 CFU/ml of bacteria in a blood sample.

55 [0064] Methods of the invention may also be combined with other separation and isolation protocols known in the art. Particularly, methods of the invention may be combined with methods shown in co-pending and co-owned U.S. patent application serial number 12/855,147, filed April 12, 2010, entitled Separating Target Analytes Using Alternating Magnetic Fields, and having Attorney Docket No.: NANO-002/00US 28864/4.

**EXAMPLES**Example 1: Sample

5 **[0065]** Blood samples from healthy volunteers were spiked with clinically relevant concentrations of bacteria (1-10 CFU/mL) including both laboratory strains and clinical isolates of the bacterial species most frequently found in blood-stream infections.

Example 2: Antibody preparation

10 **[0066]** In order to generate polyclonal, pan-Gram-positive bacteria-specific IgG, a goat was immunized by first administering bacterial antigens suspended in complete Freund's adjuvant intra lymph node, followed by subcutaneous injection of bacterial antigens in incomplete Freund's adjuvant in 2 week intervals. The antigens were prepared for antibody production by growing bacteria to exponential phase ( $OD_{600} = 0.4-0.8$ ). Following harvest of the bacteria by centrifugation, 15 the bacteria was inactivated using formalin fixation in 4% formaldehyde for 4 hr at 37 °C. After 3 washes of bacteria with PBS (15 min wash, centrifugation for 20 min at 4000 rpm) the antigen concentration was measured using BCA assay and the antigen was used at 1 mg/mL for immunization. In order to generate Gram-positive bacteria-specific IgG, several bacterial species were used for inoculation: *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Enterococcus faecium* and *Enterococcus faecalis*.

20 **[0067]** The immune serum was purified using affinity chromatography on a protein G sepharose column (GE Healthcare), and reactivity was determined using ELISA. Antibodies cross-reacting with Gram-negative bacteria and fungi were removed by absorption of purified IgG with formalin-fixed Gram-negative bacteria and fungi. The formalin-fixed organisms were prepared similar to as described above and mixed with IgG. After incubation for 2 hrs at room temperature, the preparation was centrifuged to remove bacteria. Final antibody preparation was clarified by centrifugation and used for 25 the preparation of antigen-specific magnetic beads.

Example 3: Preparation of antigen-specific magnetic beads

30 **[0068]** Superparamagnetic beads were synthesized by encapsulating iron oxide nanoparticles (5-15 nm diameter) in a latex core and labeling with goat IgG. Ferrofluid containing nanoparticles in organic solvent was precipitated with ethanol, nanoparticles were resuspended in aqueous solution of styrene and surfactant Hitenol BC-10, and emulsified using sonication. The mixture was allowed to equilibrate overnight with stirring and filtered through 1.2 and 0.45  $\mu\text{m}$  filters to achieve uniform micelle size. Styrene, acrylic acid and divinylbenzene were added in carbonate buffer at pH 9.6. The polymerization was initiated in a mixture at 70 °C with the addition of  $\text{K}_2\text{S}_2\text{O}_8$  and the reaction was allowed to 35 complete overnight. The synthesized particles were washed 3 times with 0.1% SDS using magnetic capture, filtered through 1.2, 0.8, and 0.45  $\mu\text{m}$  filters and used for antibody conjugation.

**[0069]** The production of beads resulted in a distribution of sizes that may be characterized by an average size and a standard deviation. In the case of labeling and extracting of bacteria from blood, the average size for optimal performance was found to be between 100 and 350 nm, for example between 200 nm to 250 nm.

40 **[0070]** The purified IgG were conjugated to prepared beads using standard chemistry. After conjugation, the beads were resuspended in 0.1% BSA which is used to block non-specific binding sites on the bead and to increase the stability of bead preparation.

Example 4: Labeling of rare cells using excess of magnetic nanoparticles

45 **[0071]** Bacteria, present in blood during blood-stream infection, were magnetically labeled using the superparamagnetic beads prepared in Example 3 above. The spiked samples as described in Example 1 were diluted 3-fold with a Tris-based binding buffer and target-specific beads, followed by incubation on a shaking platform at 37 °C for up to 2 hr. After incubation, the labeled targets were magnetically separated followed by a wash step designed to remove blood products. See example 5 below. 50

Example 5: Magnetic capture of bound bacteria

55 **[0072]** Blood including the magnetically labeled target bacteria and excess free beads were injected into a flow-through capture cell with a number of strong rare earth bar magnets placed perpendicular to the flow of the sample. With using a flow chamber with flow path cross-section 0.5 mm x 20 mm (h x w) and 7 bar NdFeB magnets, a flow rate as high as 5 mL/min was achieved. After flowing the mixture through the channel in the presence of the magnet, a wash solution including heparin was flowed through the channel. The bound targets were washed with heparin-containing buffer one

time to remove blood components and to reduce formation of magnetic particle aggregates. In order to effectively wash bound targets, the magnet was removed and captured magnetic material was resuspended in wash buffer, followed by re-application of the magnetic field and capture of the magnetic material in the same flow-through capture cell.

[0073] Removal of the captured labeled targets was possible after moving magnets away from the capture chamber and eluting with flow of buffer solution.

## Claims

1. A method for isolating a target analyte from a body fluid sample, the method comprising the steps of:

mixing, in a container, a body fluid sample and a buffer that substantially prevents lysis of cells and reduces non-specific binding to magnetic particles, thereby to form a diluted body fluid sample, wherein the buffer comprises Tris(hydroxymethyl)-aminomethane hydrochloride at a concentration of 75 mM, 300 mM NaCl, and 0.1% Tween 20, and wherein the buffer is mixed in a ratio of about 1:1 with the body fluid sample; introducing magnetic particles comprising a target-specific binding moiety to the diluted body fluid sample in the container in order to create a mixture, wherein the magnetic particles have an average diameter from 200 to 250 nm; incubating said mixture in the container to allow said particles to bind to a target to form target/magnetic particle complexes prior to introducing the mixture to a channel, the channel having a surface upon which to capture the target/magnetic particle complexes and being located within a fluidic device;

flowing the mixture through the channel;

applying a magnetic field to capture target/magnetic particle complexes on the surface;

washing with a wash solution that reduces particle aggregation;

removing the magnetic field;

re-introducing the wash solution, thereby re-suspending the target/magnetic particle complexes; and

flowing the re-suspended target/magnetic particle complexes over the surface in the presence of a re-applied magnetic field, thereby capturing the target/magnetic particle complexes.

2. The method according to claim 1, wherein said target-specific binding moiety is an antibody, and optionally the antibody is specific for bacteria or fungi.

3. The method according to claim 1 or claim 2, wherein said particles are superparamagnetic beads.

4. The method according to claim 1 or claim 2, wherein said body fluid is selected from blood, sputum, urine, saliva, sweat, and cerebral spinal fluid.

5. The method according to claim 4, wherein said magnetic particles comprise at least 70% superparamagnetic beads by weight.

6. The method according to claim 3, wherein the bacteria is gram positive bacteria or gram negative bacteria.

7. The method according to claim 3, wherein said bacteria is selected from E. coli, Listeria, Clostridium, Mycobacterium, Shigella, Borrelia, Campylobacter, Bacillus, Salmonella, Staphylococcus, Enterococcus, Pneumococcus, Streptococcus, and a combination thereof.

8. The method according to claim 1 or claim 2, wherein the magnetic particle is an iron containing magnetic particle and the particle optionally comprises iron oxide or iron platinum.

9. The method according to claim 1 or claim 2, further comprising lysing the captured bacteria and extracting DNA for further analysis by PCR, microarray hybridization or sequencing.

## Patentansprüche

1. Verfahren zur Isolierung eines Zielanalyten aus einer Körperflüssigkeitsprobe, wobei das Verfahren die folgenden Schritte umfasst:

Mischen, in einem Behälter, einer Körperflüssigkeitsprobe und eines Puffers, der im Wesentlichen die Lyse der

## EP 2 561 360 B1

Zellen verhindert und die nicht spezifische Bindung an magnetische Partikel reduziert, um dadurch eine verdünnte Körperflüssigkeitsprobe zu bilden, wobei der Puffer Tris(hydroxymethyl)-aminomethanhydrochlorid in einer Konzentration von 75 mM, 300 mM NaCl und 0,1 % Tween 20 umfasst, und wobei der Puffer in einem Verhältnis von ungefähr 1:1 mit der Körperflüssigkeitsprobe gemischt wird;

Einführen von magnetischen Partikeln, umfassend eine zielspezifische Bindekomponente in die verdünnte Körperflüssigkeitsprobe im Behälter, um eine Mischung zu erzeugen, wobei die magnetischen Partikel einen durchschnittlichen Durchmesser von 200 bis 250 nm aufweisen;

Inkubieren der Mischung im Behälter, um zu ermöglichen, dass die Partikel an ein Ziel binden, um Ziel-/magnetische Partikelkomplexe vor der Einführung der Mischung in einen Kanal zu bilden, wobei der Kanal eine Oberfläche aufweist, auf der die Ziel-/magnetischen Partikelkomplexe erfasst werden, und sich innerhalb der fluidischen Vorrichtung befindet;

Führen der Mischung durch den Kanal;

Anwenden eines magnetischen Felds, um die Ziel-/magnetischen Partikelkomplexe auf der Oberfläche zu erfassen;

Waschen mit einer Waschlösung, die die Partikelaggregation reduziert;

Entfernen des magnetischen Felds;

Wiedereinführen der Waschlösung, dadurch Wiedersuspendieren der Ziel-/magnetischen Partikelkomplexe; und

Führen der wiedersuspendierten Ziel-/magnetischen Partikelkomplexe über die Oberfläche in Anwesenheit eines wiederangewendeten magnetischen Felds, dadurch Erfassen der Ziel-/magnetischen Partikelkomplexe.

2. Verfahren nach Anspruch 1, wobei die zielspezifische Bindekomponente ein Antikörper ist und optional der Antikörper spezifisch für Bakterien oder Pilze ist.

3. Verfahren nach Anspruch 1 oder Anspruch 2, wobei die Partikel superparamagnetische Kügelchen sind.

4. Verfahren nach Anspruch 1 oder Anspruch 2, wobei die Körperflüssigkeit ausgewählt ist aus Blut, Auswurf, Urin, Speichel, Schweiß und Gehirn-Rückenmarks-Flüssigkeit.

5. Verfahren nach Anspruch 4, wobei die magnetischen Partikel mindestens 70 Gew% superparamagnetische Kügelchen umfassen.

6. Verfahren nach Anspruch 3, wobei die Bakterien grampositive Bakterien oder gramnegative Bakterien sind.

7. Verfahren nach Anspruch 3, wobei die Bakterien ausgewählt sind aus E. coli, Listeria, Clostridium, Mycobacterium, Shigella, Borrelia, Campylobacter, Bacillus, Salmonella, Staphylococcus, Enterococcus, Pneumococcus, Streptococcus und einer Kombination daraus.

8. Verfahren nach Anspruch 1 oder Anspruch 2, wobei der magnetische Partikel ein eisenhaltiger magnetischer Partikel ist und der Partikel optional Eisenoxid oder Eisenplatin umfasst.

9. Verfahren nach Anspruch 1 oder Anspruch 2, weiter umfassend Lyse der erfassten Bakterien und Extrahieren der DNA zur weiteren Analyse durch PCR, Microarray-Hybridisierung oder Sequenzierung.

### Revendications

1. Procédé pour isoler un analyte cible à partir d'un échantillon de fluide corporel, le procédé comprenant les étapes consistant à :

mélanger, dans un récipient, un échantillon de fluide corporel et un tampon qui empêche essentiellement la lyse des cellules et réduit la liaison non-spécifique à des particules magnétiques, pour ainsi former un échantillon de fluide corporel dilué, où le tampon comprend de l'hydrochlorure de tris(hydroxyméthyl)-aminométhane à une concentration de 75 mM, du NaCl 300 mM, et du Tween 20 à 0,1 %, et où le tampon est mélangé selon un rapport d'environ 1:1 avec l'échantillon de fluide corporel ;

introduire des particules magnétiques comprenant un fragment de liaison spécifique d'une cible dans l'échantillon de fluide corporel dilué dans le récipient afin de créer un mélange, où les particules magnétiques possèdent un diamètre moyen compris entre 200 et 250 nm ;

## EP 2 561 360 B1

incuber ledit mélange dans le récipient pour permettre auxdites particules de se lier à une cible afin de former des complexes cible/particule magnétique avant d'introduire le mélange dans un canal, le canal possédant une surface sur laquelle sont capturés les complexes cible/particule magnétique et étant localisé dans un dispositif

5 faire circuler le mélange à travers le canal ;  
appliquer un champ magnétique pour capturer les complexes cible/particule magnétique sur la surface ;  
laver avec une solution de lavage qui réduit l'agrégation des particules ;  
retirer le champ magnétique ;  
réintroduire la solution de lavage, en remettant ainsi en suspension les complexes cible/particule magnétique ; et  
10 faire circuler les complexes cible/particule magnétique remis en suspension sur la surface en présence d'un champ magnétique réappliqué, en capturant ainsi les complexes cible/particule magnétique.

2. Procédé selon la revendication 1, dans lequel ledit fragment de liaison spécifique à une cible est un anticorps, et facultativement l'anticorps est spécifique pour des bactéries ou des champignons.  
15
3. Procédé selon la revendication 1 ou la revendication 2, dans lequel lesdites particules sont des billes superparamagnétiques.
4. Procédé selon la revendication 1 ou la revendication 2, dans lequel ledit fluide corporel est sélectionné parmi du sang, des expectorations, de l'urine, de la salive, de la sueur, et du liquide céphalo-rachidien.  
20
5. Procédé selon la revendication 4, dans lequel lesdites particules magnétiques comprennent au moins 70 % de billes superparamagnétiques en poids.
- 25 6. Procédé selon la revendication 3, dans lequel les bactéries sont des bactéries à gram positif ou des bactéries à gram négatif.
7. Procédé selon la revendication 3, dans lequel lesdites bactéries sont sélectionnées parmi E. coli, Listeria, Clostridium, Mycobacterium, Shigella, Borrelia, Campylobacter, Bacillus, Salmonella, Staphylococcus, Enterococcus, Pneumococcus, Streptococcus, et une combinaison de celles-ci.  
30
8. Procédé selon la revendication 1 ou la revendication 2, dans lequel la particule magnétique est une particule magnétique contenant du fer et la particule comprend facultativement de l'oxyde de fer ou du fer-platine.
- 35 9. Procédé selon la revendication 1 ou la revendication 2, comprenant en outre la lyse des bactéries capturées et l'extraction de l'ADN pour une analyse supplémentaire par PCR, une hybridation sur microréseau ou un séquençage.

40

45

50

55

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- US 3970518 A [0017]
- US 4230685 A, Senyi [0017]
- US 4677055 A, Dodin [0017]
- US 4695393 A, Whitehead [0017]
- US 5695946 A, Benjamin [0017] [0032]
- US 4018886 A, Giaever [0017]
- US 4267234 A, Rembaum [0017]
- US 4452773 A, Molday [0017]
- US 4554088 A, Whitehead [0017]
- US 4659678 A, Forrest [0017]
- US 5186827 A, Liberti [0017] [0032]
- US 4795698 A, Own [0017]
- WO 9102811 A, Liberti [0017]
- US 6551843 B, Rao [0032]
- US 5622831 A, Liberti [0032]
- US 6514415 B, Hatch [0032]
- US 5541072 A, Wang [0032]
- US 5466574 A, Liberti [0032]
- US 6623983 B, Terstappen [0032]
- US 5089386 A, Stackebrandt [0040]
- WO 9008841 A, King [0040]
- WO 9215883 A, Foster [0040]
- WO 8906699 A, Cossart [0040]
- WO 9208805 A, Verhoef [0044]
- US 85514710 A [0064]

## Non-patent literature cited in the description

- **JANEWAY**. Immunobiology. Garland Science Publishing [0012]
- **HARLOW et al.** Antibodies. Cold Spring Harbor Laboratory, 1988, 93-117 [0025]
- **INAI et al.** *Histochemistry*, May 1993, vol. 99 (5), 335-362 [0026]
- **MULDER et al.** *Hum. Immunol.*, 1993, vol. 36 (3), 186-192 [0026]
- **HARADA et al.** *J. Oral Pathol. Med.*, 1993, vol. 22 (4), 145-152 [0026]
- **STAUBER et al.** *J. Immunol. Methods*, 1993, vol. 161 (2), 157-168 [0026]
- **VENKATESWARAN et al.** *Hybridoma*, 1992, vol. 11 (6), 729-739 [0026]
- **VERMUNT et al.** *J. Appl. Bact.*, 1992, vol. 72, 112 [0027]
- **JOHNE et al.** *J. Clin. Microbiol.*, 1989, vol. 27, 1631 [0027]
- **SKJERVE et al.** *Appl. Env. Microbiol.*, 1990, vol. 56, 3478 [0027]
- **LUND et al.** *J. Clin. Microbiol.*, 1991, vol. 29, 2259 [0027]
- **HARLOW et al.** Antibodies. Cold Spring Harbor Laboratory, 1988 [0028]
- **HUNTER et al.** Immunoassays for Clinical Chemistry. Churchill Livingstone, 1983, 147-162 [0028]
- **STANLEY.** *Essentials in Immunology and Serology*, Delmar, 2002, 152-153 [0028]
- **HIJMANS, W. et al.** *Clin. Exp. Immunol.*, 1969, vol. 4, 457 [0045]
- **GODING, J. W.** *J. Immunol. Meth.*, 1976, vol. 13, 215 [0045]
- **INGRALL, E.** *Meth. in Enzymol.*, 1980, vol. 70, 419-439 [0045]
- **SILLERUD et al.** *JMR (Journal of Magnetic Resonance)*, 2006, vol. 181 [0050]

专利名称(译)	从体液中分离目标分析物		
公开(公告)号	<a href="#">EP2561360A4</a>	公开(公告)日	2013-11-13
申请号	EP2011772606	申请日	2011-04-20
[标]申请(专利权)人(译)	NANOMR		
申请(专利权)人(译)	NANOMR INC.		
当前申请(专利权)人(译)	NANOMR INC.		
[标]发明人	CLARIZIA LISA JO ANN ADAMS EDDIE W DRYGA SERGEY A		
发明人	CLARIZIA, LISA-JO, ANN ADAMS, EDDIE, W. DRYGA, SERGEY, A.		
IPC分类号	G01N33/553 C12Q1/68 G01N33/53		
CPC分类号	C07K1/22 C07K16/1267 C12N13/00 C12Q1/6806 G01N33/54333 Y10T428/2982 C12Q2565/629 C12Q2563/143 A61B5/055 B01L3/502761 B01L2200/0647 B01L2400/043 C12N15/1013 C12Q1/689 C12Q2565/633 G01N24/08 G01N33/54326 G01N33/56911 G01N2333/195 G01N2446/20 G01R33/465		
优先权	61/326588 2010-04-21 US 12/850203 2010-08-04 US		
其他公开文献	EP2561360B9 EP2561360B1 EP2561360A1		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

本发明通常涉及使用磁性颗粒和交变磁场来从样品中分离目标分析物。在某些实施方案中，本发明的方法包括使样品与包括对靶分析物具有特异性的第一部分的磁性颗粒接触，从而在样品中形成靶/颗粒复合物，使样品流过包括与第二表面的至少一个表面相连的第二部分的通道。通道，对流动的样品施加交变磁场，使靶标/颗粒复合物进入表面附近以结合第二部分，而未结合的颗粒在样品中保持自由，将靶标/颗粒复合物结合到第二部分，并洗去样品中未结合的颗粒和未结合的分析物。